The company was one of many to get letters last month from the US Food and Drug Administration calling out what the agency ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is among the most promising biotech stocks to buy according to hedge funds.

ALNY's portfolio of rare disease and cardiovascular drugs is boosting revenues and reducing reliance on Amvuttra.

Alnylam Pharma ( ($ALNY) ) has issued an update. On September 30, 2025, Alnylam Pharmaceuticals entered into a Credit Agreement with Bank of ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) ranks among the best biotech stocks to buy. RBC Capital maintained its Outperform rating for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on September 19 and ...

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price target of $304.00. The company’s shares closed last ...

Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) is one of the best performing large cap stocks to buy. On September 29, Alnylam ...

In the second quarter, Tealwood Asset Management Inc. expanded its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by ...

Across the recent three months, 24 analysts have shared their insights on Alnylam Pharmaceuticals (NASDAQ:ALNY), expressing a variety of opinions spanning from bullish to bearish. Summarizing their ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has earned a consensus rating of “Moderate Buy” from the twenty-five brokerages that are currently covering the firm, Marketbeat reports.

Dublin-based Aerska launched on Wednesday with $21 million in seed funding and a technology designed to shuttle RNA ...